The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 344:1879-1887 June 21, 2001 Number 25
NextNext

Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban
Christopher P. Cannon, M.D., William S. Weintraub, M.D., Laura A. Demopoulos, M.D., Ralph Vicari, M.D., Martin J. Frey, M.D., Nasser Lakkis, M.D., Franz-Josef Neumann, M.D., Debbie H. Robertson, R.D., M.S., Paul T. DeLucca, Ph.D., Peter M. DiBattiste, M.D., C. Michael Gibson, M.D., Eugene Braunwald, M.D., for the TACTICS–Thrombolysis in Myocardial Infarction 18 Investigators

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Boden, W. E.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST-segment elevation.

Methods We enrolled 2220 patients with unstable angina and myocardial infarction without ST-segment elevation who had electrocardiographic evidence of changes in the ST segment or T wave, elevated levels of cardiac markers, a history of coronary artery disease, or all three findings. All patients were treated with aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban. They were randomly assigned to an early invasive strategy, which included routine catheterization within 4 to 48 hours and revascularization as appropriate, or to a more conservative (selectively invasive) strategy, in which catheterization was performed only if the patient had objective evidence of recurrent ischemia or an abnormal stress test. The primary end point was a composite of death, nonfatal myocardial infarction, and rehospitalization for an acute coronary syndrome at six months.

Results At six months, the rate of the primary end point was 15.9 percent with use of the early invasive strategy and 19.4 percent with use of the conservative strategy (odds ratio, 0.78; 95 percent confidence interval, 0.62 to 0.97; P=0.025). The rate of death or nonfatal myocardial infarction at six months was similarly reduced (7.3 percent vs. 9.5 percent; odds ratio, 0.74; 95 percent confidence interval, 0.54 to 1.00; P<0.05).

Conclusions In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events. These data support a policy involving broader use of the early inhibition of glycoprotein IIb/IIIa in combination with an early invasive strategy in such patients.


Source Information

From the Cardiovascular Division, Brigham and Women's Hospital, Boston (C.P.C., E.B.); Emory University, Atlanta (W.S.W.); Merck, West Point, Pa. (L.A.D., D.H.R., P.T.D., P.M.D.); Holmes Regional Medical Center, Melbourne, Fla. (R.V.); the Heart Center of Sarasota, Sarasota, Fla. (M.J.F.); Baylor College of Medicine, Houston (N.L.); Medizinische Klinik der Technischen Universität München, Munich, Germany (F.-J.N.); and Harvard Clinical Research Institute, Boston (C.M.G.).

Address reprint requests to Dr. Cannon at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at cpcannon{at}partners.org.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.